1-morpholino-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol | 55582-19-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-morpholino-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol
• 英文别名: 6-methyl-1-morpholin-4-yl-1,3-dihydro-furo[3,4-c]pyridin-7-ol；morpholine pyridoxal-4.5-aminal；6-Methyl-1-morpholino-1,3-dihydrofuro[3,4-c]pyridin-7-ol；6-methyl-1-morpholin-4-yl-1,3-dihydrofuro[3,4-c]pyridin-7-ol
• CAS: 55582-19-9
• 化学式: C₁₂H₁₆N₂O₃
• 分子量: 236.271
• InChiKey: WBUUALONSKFMFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  54.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-morpholino-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol 生成 磷酸吡哆醛
  参考文献：
  名称：

  NAKAGAVA, KUNIO;JOSIMURA, IKUO

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(三甲基硅基)吗啉 、 吡哆醛 以 苯 为溶剂， 反应 2.0h， 以56%的产率得到1-morpholino-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol
  参考文献：
  名称：

  Synthesis of aminofuropyridines via the reaction of aminosilanes with pyridoxal

  摘要：

  DOI：

  10.1134/s1070363214060322

文献信息

• Therapeutics for cardiovascular and related diseases
  申请人：The University of Manitoba

  公开号：US06339085B1

  公开（公告）日：2002-01-15

  Pyridoxal analogues can be useful for treating B6 efficiency and related diseases; cardiovascular and related diseases; melanoma and related diseases; and symptoms thereof. One such analogue is a compound of the formula: or a pharmaceutically acceptable acid addition salt thereof, in which R1 is alkyl, alkenyl, in which alkyl or alkenyl can be interrupted by nitrogen, oxygen, or sulfur, and can be substituted at the terminal carbon by hydroxy, alkoxy, alkanoyloxy, alkanoyloxyaryl, alkoxyalkanoyl, alkoxycarbonyl, or dialkylcarbamoyloxy; alkoxy; dialkylamino; alkanoyloxy; alkanoyloxyaryl; alkoxyalkanoyl; alkoxycarbonyl; dialkylcarbamoyloxy; or aryl, aryloxy, arylthio, or aralkyl, in which aryl can be substituted by alkyl, alkoxy, amino, hydroxy, halo, nito, or alkanoyloxy. These analogues can be administered, either alone or concurrently with known medications, to treat the above-described diseases.

  吡啶醛类似物可以用于治疗B6缺乏及相关疾病；心血管及相关疾病；黑色素瘤及相关疾病；以及相关症状。其中一种类似物是符合以下结构式的化合物：或其药学上可接受的酸盐，其中R1为烷基、烯基，其中烷基或烯基可以被氮、氧或硫中断，并且可以在末端碳上被羟基、烷氧基、烷酰氧基、烷酰氧基芳基、烷氧基烷酰基、烷氧基羰基、或二烷基氨基氧基取代；烷氧基；二烷基氨基；烷酰氧基；烷酰氧基芳基；烷氧基烷酰基；烷氧基羰基；二烷基氨基氧基；或芳基、芳基氧基、芳基硫基、或芳基烷基，其中芳基可以被烷基、烷氧基、氨基、羟基、卤素、硝基、或烷酰氧基取代。这些类似物可以单独或与已知药物同时使用，用于治疗上述疾病。
• Treatment of cerebrovascular disease
  申请人：——

  公开号：US20010056081A1

  公开（公告）日：2001-12-27

  A method of treating a cerebrovascular disease, particularly stroke, is described. A method of treating a cerebrovascular disease includes administering pyridoxal-5′-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.

  本发明涉及一种治疗脑血管疾病，特别是中风的方法。治疗脑血管疾病的方法包括给予吡哆醛-5'-磷酸、吡哆醛、吡哆醇、吡哆胺、吡哆醛的3-酰化类似物、吡哆醛-4,5-二胺的3-酰化类似物、吡哆醇磷酸酯类似物或其药物组合物。
• Use of pyridoxal phosphate for the treatment of diabetes and related complications
  申请人：Medicure Inc.

  公开号：EP1493443A1

  公开（公告）日：2005-01-05

  Use ofpyridoxal-5'-phosphate, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof for the preparation of a medicament for treating insulin-dependent or non-insulin-dependent diabetes mellitus, related conditions, symptoms of insulin-dependent or non-insulin-dependent diabetes mellitus, or related conditions, or any combination thereof in a mammal.

  吡哆醛-5'-磷酸、其药学上可接受的酸加成盐或其混合物用于制备治疗哺乳动物的胰岛素依赖型或非胰岛素依赖型糖尿病、相关病症、胰岛素依赖型或非胰岛素依赖型糖尿病症状或相关病症或其任何组合的药物。
• Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin B6
  申请人：Medicure International Inc.

  公开号：EP1640005A2

  公开（公告）日：2006-03-29

  Pyridoxal analogues can be useful for treating B6 deficiency and related diseases; cardiovascular and related diseases; melanoma and related diseases; and symptoms thereof. The analogues have formula (V) or a pharmaceutically acceptable acid addition salt thereof, in which R1 is alkyl, alkenyl, in which alkyl or alkenyl can be interrupted by nitrogen, oxygen, or sulfur, and can be substituted at the terminal carbon by hydroxy, alkoxy, alkanoyloxy, alkanoyloxyaryl, alkoxyalkanoyl, alkoxycarbonyl, or dialkylcarbamoyloxy; alkoxy; dialkylamino; alkanoyloxy; alkanoyloxyaryl; alkoxyalkanoyl; alkoxycarbonyl; dialkylcarbamoyloxy; or aryl, aryloxy, arylthio, or aralkyl, in which aryl can be substituted by alkyl, alkoxy, amino, hydroxy, halo, nito, or alkanoyloxy. R<2> is secondary amine. These analogues can be administered, either alone or concurrently with known medications, to treat the above-described diseases.

  吡哆醛类似物可用于治疗 B6 缺乏症和相关疾病、心血管疾病和相关疾病、黑色素瘤和相关疾病及其症状。这些类似物具有式（V）或其药学上可接受的酸加成盐，其中 R1 是烷基、烯基，其中烷基或烯基可以被氮、氧或硫中断，并且可以在末端碳上被羟基、烷氧基、烷酰氧基、烷酰氧基芳基、烷氧基烷酰基、烷氧基羰基或二烷基氨基甲酰氧基取代；烷氧基；二烷基氨基；烷酰氧基；烷酰氧基芳基；烷氧基烷酰基；烷氧羰基；二烷基氨基甲酰氧基；或芳基、芳氧基、芳硫基或芳烷基，其中芳基可被烷基、烷氧基、氨基、羟基、卤代、硝基或烷酰氧基取代。R 是仲胺。这些类似物可单独使用或与已知药物同时使用，以治疗上述疾病。
• use of pyridoxal phosphate for the treatment of diabetes and related complications
  申请人：Medicure Inc.

  公开号：EP1832291A2

  公开（公告）日：2007-09-12

  Use of pyridoxal-5'-phosphate, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof for the preparation of a medicament for treating insulin-dependent or non-insulin-dependent diabetes mellitus, related conditions, symptoms of insulin-dependent or non-insulin-dependent diabetes mellitus, or related conditions, or any combination thereof in a mammal.

  吡哆醛-5'-磷酸、其药学上可接受的酸加成盐或其混合物用于制备治疗哺乳动物的胰岛素依赖型或非胰岛素依赖型糖尿病、相关病症、胰岛素依赖型或非胰岛素依赖型糖尿病症状或相关病症或其任何组合的药物。